Skip to content
DraconiticResearch
Search Sources API
226,742 studies31 sourcesUpdated 52 min ago
Peer-reviewedCC BY-NCInternational Journal of Nanomedicine

Stimuli-Responsive Nanocarriers for Transdermal siRNA Delivery: Mechanisms, Challenges, and Therapeutic Strategies

7 affiliations
  1. 1School of Life Science and Medicine, Shandong University of Technology, Zibo, 244000, People's Republic of China
  2. 2School of Medical Informational Engineering, Shandong University of Traditional Chinese Medicine, Jinan, 250355, People's Republic of China
  3. 3Co-Innovation Center for the Sustainable Forestry in Southern China and Department of Food Science and Technology, Nanjing, 210037, People's Republic of China
  4. 4College of Light Industry and Food Engineering, Nanjing Forestry University, Nanjing, 210037, People's Republic of China
  5. 5Department of Clinical Medicine, The First Clinical Medical College, Jinzhou Medical University, Jinzhou, 121001, People's Republic of China
  6. 6Department of Medical Laboratory Technology, School of Medicine, Hunan Normal University, Changsha, 410006, People's Republic of China
  7. 7Laboratory of Neurological Diseases and Brain Function, the Affiliated Hospital, Southwest Medical University, Luzhou, 646000, People's Republic of China

Abstract

Background: Small interfering RNA (siRNA) holds therapeutic promise for dermatological diseases, but clinical translation is limited by the stratum corneum barrier and the instability of naked siRNA. Nanocarrier-based systems offer effective solutions by enhancing skin penetration, improving siRNA stability, and enabling targeted intracellular delivery. Methods: This review synthesizes current evidence on nanocarrier-mediated transdermal siRNA delivery. Key design parameters: particle size, surface charge, degradability, and morphology are evaluated for their roles in skin permeation and intracellular trafficking. Stimuli-responsive nanocarriers (pH, enzymatic, light, temperature) and physical enhancement strategies, including microneedles, sonophoresis, and laser ablation, are also reviewed. Results: Lipid-polymer hybrid nanoparticles demonstrate notable advantages in stability, biocompatibility, and co-delivery capability. Stimuli-responsive systems enable spatiotemporal control of siRNA release, while physical enhancement technologies significantly improve cutaneous permeability. Disease-specific delivery strategies tailored to pathological microenvironments including psoriasis, melanoma, and chronic wounds illustrate the feasibility of adapting material composition, structural parameters, and responsiveness to different therapeutic contexts. Conclusion: Advances in intelligent nanomaterials, responsive carrier engineering, and physical facilitation approaches provide a solid foundation for clinically viable transdermal siRNA therapies. Future development will benefit from integrating precise release control with disease-tailored delivery strategies to overcome biological barriers and optimize therapeutic outcomes.

Related

  1. Next-generation microneedle platforms for transdermal therapeutics: a comprehensive review of innovations and challenges
    Nabil K. Alruwaili
    3 BiotechPeer-reviewedLicence not statedFull textPharmacology & toxicologyPMC
  2. Advanced cell-laden hydrogels for diabetic wound healing: Biomaterial design, therapeutic mechanisms, and translational challenges
    Fatemeh Haghdoost, Soroush Shams, Atefeh Shahbazi +2
    Iranian Journal of Burns and Wound ResearchPeer-reviewedCC BY-NCFull textGeneral medicineDOAJ
  3. Targeting neddylation in cancer: molecular mechanisms, translational advances, and therapeutic challenges
    Xin Tian, Xinghan Li, Dequan Liu +2
    Frontiers in PharmacologyPeer-reviewedCC BY 4.0Full textPharmacology & toxicologyCrossrefPMC
  4. Advancements in therapeutic targets and drug development for hyperuricemia: Mechanisms, progress, and challenges
    Kexin Zhou, Lin Zhou, Zile Li +5
    Experimental and Molecular PathologyPeer-reviewedCC BYFull textGeneral medicineDOAJ
  5. Microarray patches for transdermal drug delivery: a critical narrative review of technological innovations, CMC challenges, clinical translation, and global health implementation
    Priyabrata Pattnaik, Lawrence Sena Tuglo, Mohammed Alissa +7
    Journal of Pharmacy & Pharmaceutical SciencesPeer-reviewedCC BYFull textPharmacology & toxicologyDOAJ
BibTeX
@article{jian2026stimuliresponsive,
  title = {{Stimuli-Responsive Nanocarriers for Transdermal siRNA Delivery: Mechanisms, Challenges, and Therapeutic Strategies}},
  author = {Yanmin Jian and Minghui Ban and Zhenyang Yan and Yue Wang and Ziyan Che and Wenwen Ren and Yuan Cao and Zao Wang and Yue Yuan},
  journal = {International Journal of Nanomedicine},
  year = {2026},
  month = jun,
  doi = {10.2147/ijn.s595572},
  url = {https://doi.org/10.2147/ijn.s595572},
  note = {CC BY-NC},
}
RIS
TY  - JOUR
TI  - Stimuli-Responsive Nanocarriers for Transdermal siRNA Delivery: Mechanisms, Challenges, and Therapeutic Strategies
AU  - Yanmin Jian
AU  - Minghui Ban
AU  - Zhenyang Yan
AU  - Yue Wang
AU  - Ziyan Che
AU  - Wenwen Ren
AU  - Yuan Cao
AU  - Zao Wang
AU  - Yue Yuan
PY  - 2026
DA  - 2026/06/01
JO  - International Journal of Nanomedicine
DO  - 10.2147/ijn.s595572
UR  - https://doi.org/10.2147/ijn.s595572
AB  - Background: Small interfering RNA (siRNA) holds therapeutic promise for dermatological diseases, but clinical translation is limited by the stratum corneum barrier and the instability of naked siRNA. Nanocarrier-based systems offer effective solutions by enhancing skin penetration, improving siRNA stability, and enabling targeted intracellular delivery. Methods: This review synthesizes current evidence on nanocarrier-mediated transdermal siRNA delivery. Key design parameters: particle size, surface charge, degradability, and morphology are evaluated for their roles in skin permeation and intracellular trafficking. Stimuli-responsive nanocarriers (pH, enzymatic, light, temperature) and physical enhancement strategies, including microneedles, sonophoresis, and laser ablation, are also reviewed. Results: Lipid-polymer hybrid nanoparticles demonstrate notable advantages in stability, biocompatibility, and co-delivery capability. Stimuli-responsive systems enable spatiotemporal control of siRNA release, while physical enhancement technologies significantly improve cutaneous permeability. Disease-specific delivery strategies tailored to pathological microenvironments including psoriasis, melanoma, and chronic wounds illustrate the feasibility of adapting material composition, structural parameters, and responsiveness to different therapeutic contexts. Conclusion: Advances in intelligent nanomaterials, responsive carrier engineering, and physical facilitation approaches provide a solid foundation for clinically viable transdermal siRNA therapies. Future development will benefit from integrating precise release control with disease-tailored delivery strategies to overcome biological barriers and optimize therapeutic outcomes.
SN  - 1176-9114
SN  - 1178-2013
ER  -